Obesity
Quantifying the impact of newer drugs to reverse the upward trend
...
properties.trackTitle
properties.trackSubtitle
By 2035, more than half of the global population is predicted to be overweight or obese, posing substantial challenges for insurers, policymakers, and healthcare providers. Newer obesity medications offer promising weight loss outcomes, having the potential to reduce morbidity and mortality rates. Insurers need to stay ahead of the curve in understanding the impact of newer treatments on insurance portfolios and develop effective strategies for managing obesity-related risks.
Munich Re's Life Science Report provides a comprehensive guide to assessing both the promises and pitfalls of emerging medical trends and risks, helping life and health insurers to better navigate this environment of changing mortality and morbidity. The report examines the topics of Artificial Intelligence in Healthcare, Improving Cancer Outcomes, Prevention, Obesity and Climate Change.
Obesity – Key Facts
Global obesity prevalence is expected to increase through 2035.
Adverse health risks caused by obesity will continue to increase mortality and morbidity.
Newer obesity medications have shown unprecedented weight loss outcomes and could potentially reverse the upward trend in obesity, reducing morbidity and mortality.
To quantify the potential future benefits of newer obesity drugs for insurance portfolios, we analyzed available North American data to project the impact on individuals for both severe and non-severe obesity.
Obesity
Explore the Life Science Report
Contact our experts
North America
/Gina%20Guzman.jpg/_jcr_content/renditions/original./Gina%20Guzman.jpg "Gina Guzman")
/Brad%20Heltemes.jpg/_jcr_content/renditions/original./Brad%20Heltemes.jpg "Bradley Heltemes")
Europe & Latin America
Asia Pacific, Middle East & Africa
- Email aarmuss@munichre.com
- vCard Download
